Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADAP Adaptimmune Therapeutics	$0.24 -4.3%	$0.27	$0.20 ▼ $1.48	$67.06M	2.24	1.69 million shs	1.29 million shs
CLSD Clearside Biomedical	$0.81 -3.5%	$0.83	$0.70 ▼ $1.65	$65.28M	2.06	359,914 shs	104,132 shs
CVM CEL-SCI	$2.44 +1.2%	$4.87	$1.98 ▼ $66.60	$7.40M	0.27	76,146 shs	63,480 shs
EXOZ eXoZymes	$9.73 -5.0%	$12.65	$8.50 ▼ $23.99	$85.69M	N/A	5,194 shs	69,125 shs

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADAP Adaptimmune Therapeutics	-4.27%	-5.39%	-13.59%	+17.57%	-70.87%
CLSD Clearside Biomedical	-3.45%	+2.66%	-1.06%	-14.63%	-32.98%
CVM CEL-SCI	+1.24%	+6.55%	-2.79%	-65.93%	-92.99%
EXOZ eXoZymes	-4.98%	-21.21%	-30.45%	-2.60%	+972,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADAP Adaptimmune Therapeutics	3.1562 of 5 stars	4.1	5.0	0.0	0.0	2.3	0.8	0.0
CLSD Clearside Biomedical	2.6514 of 5 stars	3.5	5.0	0.0	0.0	3.3	0.0	0.0
CVM CEL-SCI	0.0584 of 5 stars	0.0	2.0	0.0	0.0	0.0	0.0	0.6
EXOZ eXoZymes	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADAP Adaptimmune Therapeutics	2.29	Hold	$1.35	458.08% Upside
CLSD Clearside Biomedical	3.00	Buy	$4.75	485.70% Upside
CVM CEL-SCI	0.00	N/A	N/A	N/A
EXOZ eXoZymes	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest CVM, EXOZ, ADAP, and CLSD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/26/2025	ADAP Adaptimmune Therapeutics	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Neutral	$1.50 ➝ $0.50
5/23/2025	CLSD Clearside Biomedical	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$6.00 ➝ $5.00
5/16/2025	CLSD Clearside Biomedical	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$5.00 ➝ $5.00
5/15/2025	CLSD Clearside Biomedical	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$4.00 ➝ $3.00
5/14/2025	ADAP Adaptimmune Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$1.50 ➝ $1.00
5/14/2025	ADAP Adaptimmune Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underweight ➝ Underweight	$1.00 ➝ $0.46
4/11/2025	ADAP Adaptimmune Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
4/8/2025	CLSD Clearside Biomedical	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00 ➝ $4.00
4/1/2025	ADAP Adaptimmune Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$3.50 ➝ $3.00
3/31/2025	CLSD Clearside Biomedical	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00 ➝ $6.00
3/28/2025	CLSD Clearside Biomedical	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00 ➝ $6.00

(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADAP Adaptimmune Therapeutics	$178.03M	0.36	N/A	N/A	$0.05 per share	4.84
CLSD Clearside Biomedical	$1.66M	37.97	N/A	N/A	($0.51) per share	-1.59
CVM CEL-SCI	N/A	N/A	N/A	N/A	$0.15 per share	N/A
EXOZ eXoZymes	$70K	1,163.43	N/A	N/A	$1.25 per share	7.78

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADAP Adaptimmune Therapeutics	-$70.81M	-$0.27	N/A	N/A	N/A	-38.91%	-163.73%	-23.65%	8/11/2025 (Estimated)
CLSD Clearside Biomedical	-$34.35M	-$0.41	N/A	N/A	N/A	-818.57%	N/A	-114.23%	8/11/2025 (Estimated)
CVM CEL-SCI	-$26.92M	-$12.61	N/A	N/A	N/A	N/A	-238.05%	-104.65%	N/A
EXOZ eXoZymes	-$5.86M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Latest CVM, EXOZ, ADAP, and CLSD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	CLSD Clearside Biomedical	-$0.12	-$0.11	+$0.01	-$0.11	$0.20 million	$2.33 million
5/13/2025	Q1 2025	ADAP Adaptimmune Therapeutics	-$0.18	-$0.18	N/A	-$0.18	$6.55 million	$7.29 million
5/12/2025	Q1 2025	EXOZ eXoZymes	N/A	-$0.22	N/A	-$0.22	N/A	N/A
3/27/2025	Q4 2024	CLSD Clearside Biomedical	-$0.13	-$0.10	+$0.03	-$0.10	$0.27 million	$0.31 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADAP Adaptimmune Therapeutics	N/A	N/A	N/A	N/A	N/A
CLSD Clearside Biomedical	N/A	N/A	N/A	N/A	N/A
CVM CEL-SCI	N/A	N/A	N/A	N/A	N/A
EXOZ eXoZymes	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADAP Adaptimmune Therapeutics	4.24	2.02	1.79
CLSD Clearside Biomedical	N/A	3.19	3.19
CVM CEL-SCI	0.66	1.07	1.09
EXOZ eXoZymes	N/A	6.52	6.52

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADAP Adaptimmune Therapeutics	31.37%
CLSD Clearside Biomedical	18.75%
CVM CEL-SCI	12.08%
EXOZ eXoZymes	N/A

Insider Ownership

Company	Insider Ownership
ADAP Adaptimmune Therapeutics	12.74%
CLSD Clearside Biomedical	6.20%
CVM CEL-SCI	9.93%
EXOZ eXoZymes	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADAP Adaptimmune Therapeutics	490	265.05 million	231.28 million	Optionable
CLSD Clearside Biomedical	30	77.71 million	72.89 million	Optionable
CVM CEL-SCI	43	3.03 million	64.67 million	Optionable
EXOZ eXoZymes	29	8.37 million	N/A	N/A

CVM, EXOZ, ADAP, and CLSD Headlines

Recent News About These Companies

eXoZymes Selected as Core Industry Partner in $9M NSF-Funded Initiative to Advance Modular Cell-Free Biomanufacturing

June 26 at 4:18 PM | accessnewswire.comA

eXoZymes Increases CEO Compensation Package

June 20, 2025 | tipranks.com

Exozymes (NASDAQ:EXOZ) Trading 3.9% Higher - Here's Why

June 11, 2025 | marketbeat.com

eXoZymes Highlights Scalable Biomanufacturing Platform and First Spinout, NCTx, on Grow Everything Podcast

May 16, 2025 | accessnewswire.comA

eXoZymes Provides First Quarter 2025 and NCTx Subsidiary Update at 5PM EST Today

May 12, 2025 | accessnewswire.comA

eXoZymes to Host First Quarter 2025 and Subsidiary NCTx Update on Monday May 12, 2025, at 5PM EST

May 7, 2025 | accessnewswire.comA

eXoZymes Launches Subsidiary, NCTx, to Unlock a Promising Compound for Gut and Liver Health

May 6, 2025 | accessnewswire.comA

Bringing clarity and precision to the cell-free space by introducing exozymes

April 21, 2025 | globenewswire.com

BioClick – an enzyme engineering game-changer, launched by eXoZymes and supported by a $300K NIH grant

April 10, 2025 | globenewswire.com

eXoZymes Inc. Reports 2024 Progress and IPO Success

April 2, 2025 | tipranks.com

eXoZymes appoints experienced biomanufacturing executive, Damien Perriman, as CCO

April 2, 2025 | globenewswire.com

eXoZymes Provides Fourth Quarter and Full Year 2024 Update

April 2, 2025 | globenewswire.com

eXoZymes to Host Fourth Quarter and Full Year 2024 Results Conference Call on Wednesday April 2, 2025

March 26, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CVM, EXOZ, ADAP, and CLSD Company Descriptions

Adaptimmune Therapeutics NASDAQ:ADAP

$0.24 -0.01 (-4.27%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$0.24 +0.00 (+0.74%)

As of 06/26/2025 07:37 PM Eastern

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

Clearside Biomedical NASDAQ:CLSD

$0.81 -0.03 (-3.45%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$0.81 -0.01 (-0.62%)

As of 06/26/2025 07:50 PM Eastern

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.

CEL-SCI NYSE:CVM

$2.44 +0.03 (+1.24%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$2.42 -0.02 (-0.66%)

As of 04:05 AM Eastern

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers. It is also developing products based on its proprietary technology Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company's product pipeline includes CEL-2000; CEL-4000; and CEL-5000, which are LEAPS-based product candidates in preclinical trials for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.

eXoZymes NASDAQ:EXOZ

$9.73 -0.51 (-4.98%)

As of 06/26/2025 03:53 PM Eastern

eXoZymes, Inc. is a development stage synthetic biochemical company. Its synthetic biology platform would enable the scalable exploration of many molecules and properties found in nature. The company was founded by Tyler Korman and Paul Opgenorth in April 2019 and is headquartered in Monrovia, NV.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time